epacadostat + durvalumab

Epacadostat + durvalumab is a combination therapy consisting of **epacadostat** (a potent, highly selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor) and **durvalumab** (a human monoclonal antibody targeting programmed death ligand 1 (PD-L1)). Epacadostat blocks IDO1, an intracellular enzyme that catalyzes the degradation of tryptophan, a process implicated in tumor immune escape. Durvalumab inhibits PD-L1, restoring anti-tumor T-cell activity and enhancing immune responses against cancer. This combination was studied primarily in patients with **advanced solid tumors** in open-label phase 1/2 trials (ECHO-203), including melanoma, non-small cell lung cancer (NSCLC), squamous cell cancer of the head and neck (SCCHN), pancreatic cancer, triple-negative breast cancer (TNBC), gastric or gastroesophageal junction cancer, urothelial carcinoma, and Epstein-Barr virus positive nasopharyngeal cancer. The combination showed **well-tolerated safety**, but objective response rates were low, and no significant clinical benefit was observed in several tumor types[1][3][4][6][7]. Epacadostat is developed by Incyte, and durvalumab by AstraZeneca.

Brand names

Imfinzi

Other names

Durvalumab and EpacadostatDurvalumab/EpacadostatDurvalumab + Epacadostat